Appl. No.

: 09/111,123

Filed

7/6/1998

In the Claims:

Claims 1 - 7 are pending in the patent application. Claims 8 - 20 have been withdrawn and

claims 21 - 27 have been added by this amendment.

Please amend claim 1 as follows:

1. (Amended) A fusion protein for the alleviation of symptoms associated with an autoimmune

disorder comprising an immunoglobulin or portion thereof linked to one or more T cell receptor

antagonists wherein said immunoglobulin or portion thereof comprises at least part of a domain of a

constant region of an immunoglobulin molecule and is capable of binding to an Fc receptor of an

antigen presenting cell and being endocytosed by an the antigen presenting cell to present said one

or more T cell receptor antagonists in association with endogenous MHC Class II molecules,

thereby preventing activation of autoreactive T cells specific for said T cell receptor antagonist.

2) (canceled)

3) (previously presented) The fusion protein of claim 1 wherein the immunoglobulin or portion

thereof comprises a human IgG molecule or portion thereof.

4) (previously presented) The fusion protein of claim 1 wherein said one or more T cell receptor

antagonists alleviates the symptoms associated with an autoimmune disorder selected from the

group consisting of multiple sclerosis, lupis, rheumatoid arthritis, scleroderma, insulin-dependent

diabetes and ulcerative colitis.

5) (previously presented) The fusion protein of claim 1 wherein said one or more T cell receptor

antagonists is derived from myelin basic protein.

6) (previously presented) The fusion protein of claim 1 wherein said one or more T cell receptor

antagonists is derived from proteolipid protein.

-2-

Appl. No. : 09/111,123 Filed : 7/6/1998
7) (previously presented) The fusion protein of claim 1 wherein said one or more T cell receptor antagonists is derived from myelin basic protein and from proteolipid protein.
8) (withdrawn)
9) (withdrawn)
10) (withdrawn)
11) (withdrawn)
12) (withdrawn)
13) (withdrawn)
14) (withdrawn)
15) (withdrawn)
16) (withdrawn)
17) (withdrawn)
18) (withdrawn)
19) (withdrawn)

20) (withdrawn)

Appl. No.

: 09/111,123

Filed

7/6/1998

21) (newly presented) A fusion protein for the treatment of an autoimmune disorder comprising an

immunoglobulin or portion thereof linked to one or more T cell receptor antagonists wherein said

immunoglobulin or portion thereof comprises at least part of a domain of a constant region of an

immunoglobulin molecule and is capable of binding to an Fc receptor of an antigen presenting cell

and said fusion protein being endocytosed by the antigen presenting cell to present said one or more

T cell receptor antagonists in association with endogenous MHC Class II molecules, thereby

preventing activation of autoreactive T cells specific for said one or more T cell receptor

antagonist.

22) (newly presented) A fusion protein of claim 21 wherein the immunoglobulin or portion thereof

comprises a human IgG molecule or portion thereof.

23) (newly presented) The fusion protein of claim 21 wherein said one or more T cell receptor

antagonists alleviates the symptoms associated with an autoimmune disorder selected from the

group consisting of multiple sclerosis, lupis, rheumatoid arthritis, scleroderma, insulin-dependent

diabetes and ulcerative colitis.

24) (newly presented) The fusion protein of claim 21 wherein the immunoglobulin or portion

thereof comprises a humanized IgG molecule or portion thereof.

25) (newly presented) The fusion protein of claim 21 wherein said one or more T cell receptor

antagonists is derived from myelin basic protein.

26) (newly presented) The fusion protein of claim 21 wherein said one or more T cell receptor

antagonists is derived from proteolipid protein.

27) (newly presented) The fusion protein of claim 21 wherein said one or more T cell receptor

antagonists is derived from myelin basic protein and from proteolipid protein.

-4-